Skip to main content
Erschienen in: Annals of Surgical Oncology 10/2020

18.05.2020 | Hepatobiliary Tumors

Prognostic Role of Time to Surgery in Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer Stage 0-A

verfasst von: Mengchao Wei, MD, Shuling Chen, MD, Jiali Li, MD, Bin Li, MSc, Jingxian Shen, MD, Zhenwei Peng, MD, Qian Zhou, MSc, Ying Zou, MM, Xiaofang He, MD, Shaoqiang Li, MD, Dongming Li, MD, Baogang Peng, MD, Jiaming Lai, MD, Sui Peng, MD, Beijiao Qin, MB, Ming Kuang, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Postsurgical recurrence is common in early-stage hepatocellular carcinoma (HCC). Prolonged time to surgery (TTS) may lead to tumor progression. However, the impact of TTS on HCC prognosis is controversial in Western studies and unknown in China. We aim to investigate the impact of TTS on the prognosis of Chinese HCC patients at Barcelona Clinic Liver Cancer (BCLC) stage 0-A who underwent surgery.

Patients and Methods

We retrospectively enrolled 967 BCLC 0-A HCC patients who underwent surgery at three tertiary centers in China. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS). Restricted cubic spline (RCS) was used to select the cutoff value of TTS. Propensity score matching (PSM) was performed to reduce confounding bias, and a time-dependent Cox model was utilized to investigate factors influencing TTS.

Results

The median TTS of BCLC 0-A HCC patients was 13 days (interquartile range: 10–21 days). For patients with TTS ≤ 70 days, the cutoff value of TTS was 13 days according to RCS. After PSM, corresponding 1-, 3-, and 5-year RFS of the TTS > 13 days and TTS ≤ 13 days groups were 75.6%, 55.3%, 46.4% and 71.2%, 52.3%, 38.8%, respectively (P = 0.103). Corresponding 1-, 3-, and 5-year OS of TTS > 13 days and TTS ≤ 13 days groups were 93.7%, 82.8%, 69.6% and 92.4%, 78.5%, 68.4%, respectively (P = 0.580). Time-dependent Cox analysis revealed that age and tumor size were factors influencing TTS.

Conclusions

Our study suggests that, for patients with TTS ≤ 70 days, prolonged TTS had no impact on BCLC 0-A Chinese HCC patients receiving surgery.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391:1301–14.PubMed Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391:1301–14.PubMed
2.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65:87–108.CrossRefPubMed Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65:87–108.CrossRefPubMed
3.
Zurück zum Zitat Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150:835–53.CrossRefPubMed Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150:835–53.CrossRefPubMed
4.
Zurück zum Zitat Yeung YP, Lo CM, Liu CL, et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005; 100:1995–2004.CrossRefPubMed Yeung YP, Lo CM, Liu CL, et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005; 100:1995–2004.CrossRefPubMed
5.
Zurück zum Zitat Bialecki ES, Di Bisceglie AM. Clinical presentation and natural course of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005; 17:485–9.CrossRefPubMed Bialecki ES, Di Bisceglie AM. Clinical presentation and natural course of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005; 17:485–9.CrossRefPubMed
6.
Zurück zum Zitat Huo TI, Huang YH, Chiang JH, et al. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias? Scand J Gastroenterol 2007; 42:485–92.CrossRefPubMed Huo TI, Huang YH, Chiang JH, et al. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias? Scand J Gastroenterol 2007; 42:485–92.CrossRefPubMed
7.
Zurück zum Zitat Singal AG, Waljee AK, Patel N, et al. Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 2013; 11:1101–8.CrossRefPubMedPubMedCentral Singal AG, Waljee AK, Patel N, et al. Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 2013; 11:1101–8.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Lim C, Bhangui P, Salloum C, et al. Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma. J Hepatol 2018; 68:100–8.CrossRef Lim C, Bhangui P, Salloum C, et al. Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma. J Hepatol 2018; 68:100–8.CrossRef
9.
Zurück zum Zitat Xu K, Watanabe-Galloway S, Rochling FA, et al. Surgical delay is associated with improved survival in hepatocellular carcinoma: results of the National Cancer Database. J Gastrointest Surg 2019; 23:933–43.CrossRefPubMed Xu K, Watanabe-Galloway S, Rochling FA, et al. Surgical delay is associated with improved survival in hepatocellular carcinoma: results of the National Cancer Database. J Gastrointest Surg 2019; 23:933–43.CrossRefPubMed
10.
Zurück zum Zitat Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int 2015; 35:2155–66.CrossRefPubMedPubMedCentral Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int 2015; 35:2155–66.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Tanaka M, Katayama F, Kato H, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011; 21:401–16.CrossRefPubMedPubMedCentral Tanaka M, Katayama F, Kato H, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011; 21:401–16.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Li XJ, Chen MS, Wang ZH, et al. Forgone care among middle aged and elderly with chronic diseases in China: evidence from the China Health and Retirement Longitudinal Study Baseline Survey. BMJ Open 2018; 8:1–10. Li XJ, Chen MS, Wang ZH, et al. Forgone care among middle aged and elderly with chronic diseases in China: evidence from the China Health and Retirement Longitudinal Study Baseline Survey. BMJ Open 2018; 8:1–10.
13.
Zurück zum Zitat Xiong XL, Zhang ZG, Ren J, et al. Impact of universal medical insurance system on the accessibility of medical service supply and affordability of patients in China. PLoS ONE 2018; 13:1–20. Xiong XL, Zhang ZG, Ren J, et al. Impact of universal medical insurance system on the accessibility of medical service supply and affordability of patients in China. PLoS ONE 2018; 13:1–20.
14.
Zurück zum Zitat Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67:358–80.CrossRefPubMed Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67:358–80.CrossRefPubMed
15.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240:205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240:205–13.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250:187–96.CrossRefPubMed Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250:187–96.CrossRefPubMed
17.
Zurück zum Zitat Cucchetti A, Vivarelli M, Piscaglia F, et al. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol 2005; 43:310–16.CrossRefPubMed Cucchetti A, Vivarelli M, Piscaglia F, et al. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol 2005; 43:310–16.CrossRefPubMed
18.
Zurück zum Zitat Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8:551–61.CrossRefPubMed Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8:551–61.CrossRefPubMed
19.
Zurück zum Zitat D’Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265–81.CrossRefPubMed D’Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265–81.CrossRefPubMed
20.
Zurück zum Zitat Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol 2006; 163:1149–56.CrossRefPubMed Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol 2006; 163:1149–56.CrossRefPubMed
21.
Zurück zum Zitat Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biometrical J 2009; 51:171–84.CrossRef Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biometrical J 2009; 51:171–84.CrossRef
22.
Zurück zum Zitat McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 2013; 32:3388–414.CrossRefPubMedPubMedCentral McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 2013; 32:3388–414.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Croome KP, Chudzinski R, Hanto DW. Increasing time delay from presentation until surgical referral for hepatobiliary malignancies. HPB (Oxford) 2010; 12:644–8.CrossRef Croome KP, Chudzinski R, Hanto DW. Increasing time delay from presentation until surgical referral for hepatobiliary malignancies. HPB (Oxford) 2010; 12:644–8.CrossRef
24.
Zurück zum Zitat Willatt JM, Hussain HK, Adusumilli S, et al. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247:311–30.CrossRefPubMed Willatt JM, Hussain HK, Adusumilli S, et al. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247:311–30.CrossRefPubMed
25.
Zurück zum Zitat Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg 2011; 253:779–85.CrossRefPubMed Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg 2011; 253:779–85.CrossRefPubMed
26.
Zurück zum Zitat Shin DW, Cho J, Kim SY, et al. Delay to curative surgery greater than 12 weeks is associated with increased mortality in patients with colorectal and breast cancer but not lung or thyroid cancer. Ann Surg Oncol 2013; 20:2468–76.CrossRefPubMed Shin DW, Cho J, Kim SY, et al. Delay to curative surgery greater than 12 weeks is associated with increased mortality in patients with colorectal and breast cancer but not lung or thyroid cancer. Ann Surg Oncol 2013; 20:2468–76.CrossRefPubMed
27.
Zurück zum Zitat Hanna SJ, Muneer A, Khalil KH. The 2-week wait for suspected cancer: time for a rethink? Int J Clin Pract 2005; 59:1334–9.CrossRefPubMed Hanna SJ, Muneer A, Khalil KH. The 2-week wait for suspected cancer: time for a rethink? Int J Clin Pract 2005; 59:1334–9.CrossRefPubMed
28.
Zurück zum Zitat Stec AA, Coons BJ, Chang SS, et al. Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma: does it affect survival? J Urol 2008; 179:2152–7.CrossRefPubMedPubMedCentral Stec AA, Coons BJ, Chang SS, et al. Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma: does it affect survival? J Urol 2008; 179:2152–7.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Jooste V, Dejardin O, Bouvier V, et al. Pancreatic cancer: wait times from presentation to treatment and survival in a population-based study. Int J Cancer 2016; 139:1073–80.CrossRefPubMed Jooste V, Dejardin O, Bouvier V, et al. Pancreatic cancer: wait times from presentation to treatment and survival in a population-based study. Int J Cancer 2016; 139:1073–80.CrossRefPubMed
30.
Zurück zum Zitat Helewa RM, Turner D, Park J, et al. Longer waiting times for patients undergoing colorectal cancer surgery are not associated with decreased survival. J Surg Oncol 2013; 108:378–84.CrossRefPubMed Helewa RM, Turner D, Park J, et al. Longer waiting times for patients undergoing colorectal cancer surgery are not associated with decreased survival. J Surg Oncol 2013; 108:378–84.CrossRefPubMed
Metadaten
Titel
Prognostic Role of Time to Surgery in Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer Stage 0-A
verfasst von
Mengchao Wei, MD
Shuling Chen, MD
Jiali Li, MD
Bin Li, MSc
Jingxian Shen, MD
Zhenwei Peng, MD
Qian Zhou, MSc
Ying Zou, MM
Xiaofang He, MD
Shaoqiang Li, MD
Dongming Li, MD
Baogang Peng, MD
Jiaming Lai, MD
Sui Peng, MD
Beijiao Qin, MB
Ming Kuang, MD
Publikationsdatum
18.05.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2020
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08499-2

Weitere Artikel der Ausgabe 10/2020

Annals of Surgical Oncology 10/2020 Zur Ausgabe

Health Services Research and Global Oncology

Warm and Welcoming: Is It What We Say or How We Say It?

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.